# A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting

> **NCT07073079** · — · RECRUITING · sponsor: **AbbVie** · enrollment: 250 (estimated)

## Conditions studied

- Crohn's Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07073079
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-14
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07073079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07073079, "A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07073079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*